Dziedziak Jacek, Kasarełło Kaja, Cudnoch-Jędrzejewska Agnieszka
Department of Experimental and Clinical Physiology, Center for Preclinical Research, Medical University of Warsaw, 02-097 Warsaw, Poland.
Antioxidants (Basel). 2021 Oct 30;10(11):1743. doi: 10.3390/antiox10111743.
Age-related macular degeneration (AMD) and glaucoma are ophthalmic neurodegenerative diseases responsible for irreversible vision loss in the world population. Only a few therapies can be used to slow down the progression of these diseases and there are no available treatment strategies for reversing the degeneration of the neural retina. In AMD, the pathological process causes the malfunction and damage of the retinal pigmented epithelium and photoreceptors in the macula. In glaucoma, damage of the retinal ganglion cells and their axons is observed and treatment strategies are limited to intraocular pressure lowering. Therefore, other prophylactic and/or therapeutic methods are needed. Oxidative stress is involved in the neurodegenerative process accompanying both AMD and glaucoma; therefore, the use of antioxidant agents would clearly be beneficial, which is supported by the decreased prevalence and progression of AMD in patients adherent to a diet naturally rich in antioxidants. Dietary antioxidants are easily available and their use is based on the natural route of administration. Many preclinical studies both in vitro and using animal models of retinal degeneration showed the efficacy of dietary antioxidants, which was further proved in clinical trials. Resveratrol is beneficial both in AMD and glaucoma animal models, but confirmed only among AMD patients. For AMD, carotenoids and omega-3 fatty acids were also proved to be sufficient in preventing neurodegeneration. For glaucoma, coenzyme Q10 and alpha-lipoic acid showed efficacy for decreasing retinal ganglion cell loss and inhibiting the accompanying destructive processes. Interestingly, the benefits of vitamins, especially vitamin E was not confirmed, neither in preclinical nor in clinical studies.
年龄相关性黄斑变性(AMD)和青光眼是导致全球人口不可逆视力丧失的眼科神经退行性疾病。只有少数疗法可用于减缓这些疾病的进展,目前尚无逆转神经视网膜变性的治疗策略。在AMD中,病理过程会导致黄斑区视网膜色素上皮和光感受器功能异常及损伤。在青光眼中,可观察到视网膜神经节细胞及其轴突受损,治疗策略仅限于降低眼压。因此,需要其他预防和/或治疗方法。氧化应激参与了AMD和青光眼所伴随的神经退行性过程;因此,使用抗氧化剂显然会有益处,这一点得到了坚持食用天然富含抗氧化剂饮食的患者中AMD患病率降低和病情进展减缓的支持。膳食抗氧化剂易于获取,其使用基于天然给药途径。许多体外和使用视网膜变性动物模型的临床前研究均显示了膳食抗氧化剂的疗效,这一点在临床试验中得到了进一步证实。白藜芦醇在AMD和青光眼动物模型中均有益处,但仅在AMD患者中得到证实。对于AMD,类胡萝卜素和ω-3脂肪酸也被证明足以预防神经退行性变。对于青光眼,辅酶Q10和α-硫辛酸在减少视网膜神经节细胞损失及抑制伴随的破坏过程方面显示出疗效。有趣的是,无论是临床前研究还是临床研究,均未证实维生素(尤其是维生素E)的益处。